Dr. Clay Siegall, A Master of Targeted Therapy
Dr. Clay Siegall is the Chief Operating Officer of Seattle Genetics, a biotechnology company headquartered in Seattle, Washington. Seattle Genetics is primarily focused on the development of targeted therapy for the treatment of diseases, such as cancer, that have increased mortality rates and have not seen improvement in those rates over a long period of time.
Dr. Siegall earned his bachelor of science degree in zoology from the University of Maryland. He later earned a doctorate degree in Genetics from George Washington University. In 1998, he founded Seattle Genetics with a small group of scientific researchers. Since then, his company has grown into a major player in the pharmaceutical industry. His company developed the first, novel antibody drug therapy for cancer, as well as, more than twenty different drugs used in targeted therapy. His partnerships include global manufacturers of drugs such as Genentech, Bayer, and Pfizer.
Dr. Siegall believes that the use of targeted drugs is the future direction of cancer therapy. He is confident that chemotherapy is outdated and is destined to be discontinued in the near future. He envisions targeted therapy to be more tolerable and more effective then chemotherapy. After witnessing a relative almost died from developing severe anemia during chemotherapy treatment. He also was witness to other complications such as amputation or surgery to treat cancer. He believes that there should be a better strategy and a better method in treating disease. His mission and the mission of Seattle Genetics is to overcome disease and intervene in the course of nature to restore health to those whose fate would have been death.
Dr. Clay Siegall states that he owes his success to hard work. He believes that the a good work ethic and the passion to work in a focused and intense way is how you succeed in business and in life in general. Everything else is secondary.